The IL23-IL17 immune axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges
D Noviello, R Mager, G Roda, RG Borroni… - Frontiers in …, 2021 - frontiersin.org
Ulcerative colitis (UC) is a chronic relapsing disorder of the colonic tract, characterized by a
dysregulated innate and adaptive immune response to gut microbiota that contributes to the …
dysregulated innate and adaptive immune response to gut microbiota that contributes to the …
IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality
R Atreya, MF Neurath - Journal of Crohn's and Colitis, 2022 - academic.oup.com
Increasing insights into the immunopathogenesis of inflammatory bowel diseases [IBD] have
led to the advent of targeted therapies that inhibit crucial mediators of the inflammatory …
led to the advent of targeted therapies that inhibit crucial mediators of the inflammatory …
Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23
B Steere, C Beidler, A Martin, S Bright, K Kikly… - … of Pharmacology and …, 2023 - ASPET
Interleukin (IL)-23 exists as a heterodimer consisting of p19 and p40 and is a key cytokine
for promoting inflammatory responses in a variety of target organs. IL-23 plays a key role in …
for promoting inflammatory responses in a variety of target organs. IL-23 plays a key role in …
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges
M Vecellio, R Atreya, F Scaldaferri… - Role of the IL-23/IL-17 …, 2021 - books.google.com
Ulcerative colitis (UC) is a chronic relapsing disorder of the colonic tract, characterized by a
dysregulated innate and adaptive immune response to gut microbiota that contributes to the …
dysregulated innate and adaptive immune response to gut microbiota that contributes to the …